Aflibercept appears effective in inflammatory choroidal neovascularization

Aflibercept appears to be anatomically and functionally effective in the clinical treatment of inflammatory choroidal neovascularization (CNV), according to the results of a study.

In this prospective non-comparative open-label trial, 19 patients underwent 1 mandatory intravitreal injection of aflibercept followed by a pro re nata (PRN) dosing regimen with monthly visits. A total of 16 patients were followed for the whole 52-week study and data for the primary endpoint analysis were available for 14 patients. Baseline mean BCVA was 64.53 (±19.64) letters. The mean change in BCVA at 52 weeks was +9.50 (±12.90) letters [95%CI = +2.05-+16.95]. At week 24, 1 patient had lost >15-letters and another letter at 52 weeks.

Baseline mean central retinal thickness (CRT) was 351.79 (±97.77) μm with a change of -62.77 (±100.73) μm at 24 weeks and -66.53 (±97.47) μm at 52 weeks.

There was a mean number of 3.56 (±3.29) intravitreal injections at 52 weeks with a minimum of 1 and a maximum of 12. No serious ocular adverse events related to the treatment were reported.

Reference
Kodjikian L, Abukhashabah A, Fardeau C, et al. Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study. Acta Ophthalmol. 2022;doi: 10.1111/aos.15214. Epub ahead of print. PMID: 35822428.